Results 211 to 220 of about 530,731 (290)

Pilot report of an anti-PD-1/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas. [PDF]

Cancer Immunol Immunother
Yanchu L, Hongbin W, Xiaoli Y, Li Z, Jun W, Meiling R, Xiaoyan Y, Lei L, Feng W.   +8 more
europepmc   +1 more source

BCMA Antigen Loss Through Acquired TNFRSF17 Deletion in Multiple Myeloma

International Journal of Laboratory Hematology, EarlyView.
Ali Benaboud, Rémi Tilmont, Gauthier Decool, Nicolas Gower, Salomon Manier, Benjamin Podvin   +5 more
wiley   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, Volume 101, Issue 11, Page 2713-2725, November 2026.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, Volume 115, Issue 11, Page 2603-2615, November 2026.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

Angewandte Chemie, Volume 138, Issue 42, 12 October 2026.
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco, Fabio Baroni, Angela Capolupo, Sofia Petrocchi, Jonathan Zöller, Linda Cerofolini, Pasquale Russomanno, Rebecca Calamandrei, Bianca Susini, Siyu Lin, Fabio D'Amici, Enrico Ravera, Julian Langer, Marco Fragai   +13 more
wiley   +2 more sources

Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. [PDF]

Front Oncol
Shao W, Liu Y, Huang L, Lu S, Zhai Y, Xiong Y, Chen N, Ye P, Lv Q.   +8 more
europepmc   +1 more source

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

European Journal of Haematology, Volume 117, Issue 5, Page 1181-1197, November 2026.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma. [PDF]

Blood Adv
Iacoboni G, Kyvsgaard ER, Navarro Garcés V, Russler-Germain DA, Lewis K, Martín García-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela D, Ku M, Gómez P, Valencia E, Vega G, Jiménez-Ubieto A, Bastos-Oreiro M, Serna A, Husby S, De La Cruz B, Luan J, Camarillas S, Medina L, Cabero A, Córdoba R, Canales M, Sancho JM, Bosch F, Sureda A, Schuster S, Cheah CY, Hutchings M, Barba P, Abrisqueta P.   +32 more
europepmc   +1 more source